The aim was to assess whether hepatocyte growth factor (HGF) and interleukin (IL)-6 in combination with prostate volume are able to accurately detect prostate cancer in patients with gray-zone prostate-specific antigen (PSA) levels. A total of 159 patients with PSA levels of o10 ng ml À1 were enrolled. Forty-two (35.3%) were diagnosed with prostate cancer, whereas 117 (64.7%) had no cancer and were used as benign group. HGF and IL-6 density (HGFD and IL-6D, respectively) values were calculated by dividing serum HGF and IL-6 levels with prostate volume. Median IL-6 (2.3 pg ml
Introduction
Prostate-specific antigen (PSA) is the most reliable circulation tumor marker currently available, and is widely used for diagnosis and management of prostate cancer. However, there is a large overlap between prostate cancer and benign prostatic hyperplasia diagnosis in patients with moderately increased PSA levels, especially from 4 to 10 ng ml
À1
, which is known as the 'gray-zone', 1 as a value in that zone is a poor indicator for predicting stage and prognosis. Among patients with gray-zone PSA levels, only 27% are found to have prostate cancer. 2 To improve these significant limitations of PSA testing, much effort has been given to increasing its sensitivity and specificity. Although recent enhancements in PSA testing, such as the ratio of free/total PSA levels in serum or PSA density and PSA transition density, have increased diagnostic accuracy, there is still a great need to further improve prostate cancer detection methods. 3 A number of polypeptide growth factors have been implicated in the carcinogenesis and progression of prostate cancer. Hepatocyte growth factor (HGF) was first identified and cloned as a potent mitogen for mature hepatocytes, and it is now known to elicit mitogenic, motogenic and morphogenic activities in various types of cells. 4 HGF also induces invasion of various types of cancer cells, including those associated with lung, pancreas, gall bladder and hepatocellular cancer, while it also enhances the invasive activities of prostate cancer cells through tumor-stromal interaction, and stimulation of the urokinase-type plasminogen activator (uPA) and uPA receptor proteolytic networks. 5, 6 Interleukin (IL)-6, also known as hepatocyte-stimulating factor, is a pleiotropic cytokine with a variety of effects on hematopoiesis, immune system and acutephase responses. IL-6 has also been shown to be an important stimulator for growth in a number of tumor cells, including renal cell and cervical carcinomas. 7, 8 There is also ample evidence showing that IL-6 plays an important role as an autocrine growth factor in metastatic prostate cancer by regulating androgen receptor activity. 9, 10 It was demonstrated previously that elevated serum HGF levels in prostate cancer patients were related to malignancy grade and stage, while higher plasma levels of this factor in men with hormone-refractory prostate cancer were associated with decreased patient survival. [11] [12] [13] On the other hand, elevated serum IL-6 levels in patients with prostate cancer have been associated with advanced stage and prognosis. 14, 15 These findings suggest that HGF and IL-6 are possible mediators of advanced prostate cancer morbidity and disease activity. However, to date, there are no known investigations of the association between serum HGF or IL-6 levels and prostate cancer detection in patients with gray-zone PSA levels. In the present study, we investigated whether measurement of serum HGF and IL-6 levels could lead to detection of prostate cancer in patients with gray-zone PSA levels of o10 ng ml
. Further, we analyzed those variables in combination with prostate volume using HGF density (HGFD) and IL-6 density (IL-6D) values to discriminate between subjects with prostate cancer and those with benign prostate hyperplasia.
Patients and methods
Between July 2001 and December 2003, 283 patients underwent a transrectal ultrasonography (TRUS)-guided systematic 10-core transperineal biopsy of the prostate gland due to elevated serum PSA levels at our institution, of whom 159 with PSA levels ranging from 2.7 to 10 ng ml À1 were enrolled in the present study, after providing informed consent. None had evidence of urinary tract retention, active infection or inflammatory disease, nor received previous medical treatment for any condition that may have affected serum PSA. Serum PSA levels were measured using a chemiluminescent enzyme immunoassay at our laboratory. Before the TRUS procedures, blood samples were collected and stored at À80 1C until analysis. Serum HGF and IL-6 levels were assayed by Bio Medical Laboratories.
Total prostate volume was obtained by TRUS using an ultrasound instrument (SSD 650CL, 7.5 MHz transducers; ALOKA CO., LTD, Tokyo, Japan) and estimated using a formula for prolate ellipse volume calculation (width Â length Â height Â p/6). PSA, HGF and IL-6 density (PSAD, HGFD and IL-6D, respectively) values were calculated by dividing serum PSA, HGF and IL-6 levels, respectively, with prostate volume.
Statistical analyses were performed using commercially available software. Statistical comparisons between biopsy-positive (prostate cancer group) and -negative (benign group) subjects for median age and prostate volume, as well as PSA, PSAD, HGF, HGFD, IL-6 and IL-6D levels were conducted using Mann-Whitney Utests. To evaluate differences by age, we calculated ageadjusted levels of prostate volume, PSA, PSAD, HGF, HGFD, IL-6 and IL-6D using JMP 6 Japanese Edition (SAS Institute Inc., NC, USA), and compared the results between the prostate cancer and benign groups. Receiver operating characteristic (ROC) curves were constructed for age-adjusted PSA, PSAD, HGF, HGFD, IL-6 and IL-6D values by plotting sensitivity versus specificity and the area under the curve (AUC) was analyzed using MedCalc version 9.0 (MedCalc Software, Mariakerke, Belgium). Multivariate analysis was done using logistic regression. Relationships between age-adjusted HGF and IL-6 levels and between HGFD and IL-6D values were examined using Pearson's correlation and linear regression.
Results
Of the 159 patients investigated, 42 (35.3%) were diagnosed with prostate cancer, whereas 117 (64.7%) had no cancer and were used as controls for the study. Hepatocyte growth factor and interleukin-6 K Nishimura et al Table 1 shows the clinical characteristics of the subjects, as well as various parameters and cancer detection findings. Median age was significantly higher in the prostate cancer group than the benign group (P ¼ 0.0009), while median prostate volume was significantly higher in the benign group (P ¼ 0.0009). Median serum PSA and HGF levels in the two groups were similar (P ¼ 0.3277 and 0.3632, respectively), while median serum IL-6 (P ¼ 0.0098), as well as median PSAD, HGFD and IL-6D values (P ¼ 0.0004, 0.0025 and 0.0001, respectively) were significantly higher in the prostate cancer group. Table 2 shows median prostate volume, PSA, PSAD, HGF, HGFD, IL-6 and IL-6D values, after adjustments for age in both groups. Median serum PSA and HGF levels in the two groups were similar (P ¼ 0.5041 and 0.6989, respectively). In contrast, median prostate volume was significantly higher in the benign group (P ¼ 0.0009), whereas median IL-6, PSAD, HGFD and IL-6D values were significantly higher in the prostate cancer group (P ¼ 0.0416, 0.0006, 0.007 and 0.0005, respectively).
Receiver operating characteristic analyses were performed to evaluate the relative potential of PSA, PSAD, HGF, HGFD, IL-6 and IL-6D for discriminating between prostate cancer and benign groups, after adjustments for age ( Figure 1 ). The area under the curve values were 0.53 for PSA, 0.68 for PSAD, 0.52 for HGF, 0.64 for HGFD, 0.61 for IL-6 and 0.68 for IL-6D. The areas for PSAD, HGFD and IL-6D were significantly greater than those for PSA, HGF and IL-6, respectively (P ¼ 0.0003, 0.0006 and 0.019, respectively). There were no significant differences Figure 1 Receiver operating characteristic curves for PSA and PSAD levels (a), HGF and HGFD levels (b) and IL-6 and IL-6D levels (c) when used for the detection of prostate cancer, after adjustments for age. The areas under the curves of PSAD, HGFD and IL-6D were significantly greater than those of PSA, HGF and IL-6 (P ¼ 0.0003, 0.0006 and 0.019, respectively). CI: confidence interval. Hepatocyte growth factor and interleukin-6 K Nishimura et al between PSAD and HGFD or IL-6D, or between HGFD and IL-6D (P ¼ 0.48, 0.983 and 0.425, respectively). The sensitivity, specificity and positive and negative predictive values of PSA, PSAD, HGF, HGFD, IL-6 and IL-6D were calculated at selected cutoff levels, after adjustments for age (Table 3) . With an HGFD cutoff value of 0.00541 ng ml À1 cm À3 (sensitivity ¼ 95%, specificity ¼ 25%), 24.8% of the biopsy procedures could have been avoided in the benign group, while 4.7% of the subjects with prostate cancer would have been missed. Notably, with an HGFD cutoff value of 0.00392 ng ml À1 cm
À3
(sensitivity ¼ 100%, specificity ¼ 11.1%), 11.1% of the benign control subjects could have avoided an unnecessary biopsy without missing prostate cancer. The relationships between HGF and IL-6, as well as between HGFD and IL-6D in both groups were analyzed, after adjustments for age (Figure 2 ). We found significant positive correlations between HGF and IL-6 (r ¼ 0.235, P ¼ 0.028), and between HGFD and IL-6D (r ¼ 0.521, Po0.0001). In separate analyses, there were no differences between the prostate cancer and benign groups, while there were correlations between HGF and IL-6 (r ¼ 0.272, P ¼ 0.081 and r ¼ 0.201, P ¼ 0.0301) and between HGFD and IL-6D (r ¼ 0.489, P ¼ 0.001 and r ¼ 0.472, Po0.0001) in both groups.
Discussion
Measurements of serum growth factor levels are considered to be important, because these factors in the circulation can affect local tissue concentrations and distant metastasis. A number of polypeptide growth factors detected in blood samples have been shown to be useful biomarkers for the presence, stage, progression and prognosis of prostate cancer. However, few studies have reported levels of serum growth factors in patients with gray-zone PSA levels. It is considered that human glandular kallikrein and insulin-like growth factor-1 in combination with free PSA may play useful diagnostic roles, not only in gray-zone patients, but also in those with PSA levels from 2 to 4 mg l À1 . 16 On the other hand, in patients with serum PSA levels lower than 10 ng ml À1 , serum keratinocyte growth factor levels were reported to be significantly higher in patients with benign prostatic hyperplasia as compared to those with prostate cancer. 17 In the present study, the values for PSAD were significantly higher in the prostate cancer group than the benign group, both of which had gray-zone PSA levels, while there were no significant differences in serum PSA. However, serum IL-6 was significantly higher in the prostate cancer group, as were the values for serum IL-6, HGFD and IL-6D, after adjustments for age. These positive associations of HGF and IL-6 in combination with prostate volume in patients with grayzone, PSA levels show them to be useful markers for screening of individuals with prostate cancer.
An often used prostate volume-related tumor marker is PSAD. In the present study, after adjustments for age, the values for PSAD, HGFD and IL-6D were significantly higher in the subjects with prostate cancer than those whose results were benign, while the area under the curve values of PSAD, HGFD and IL-6D were significantly greater than those for PSA, HGF and IL-6, as shown by receiver operating characteristic analyses. On the other hand, there were no significant differences between PSAD and HGFD or IL-6D. Thus, those ratios of HGFD and IL-6D may also have potential as new prostate cancer diagnostic tools as well as PSAD. HGFD and IL-6D values are determined by the level of serum HGF or IL-6, which is expressed as a quotient derived by dividing serum HGF or IL-6 by prostate volume. A comparison of PSAD is based on reported evidence that the amount of PSA released into serum is greater per gram of cancer tissue than per gram of benign prostate tissue. 18 However, in contrast to PSA, HGF and IL-6 are produced not only from prostate cells, but also from various other tissues. Thus, high levels of these growth factors might be the result of responses to other inducing factors secreted from prostate cancer cells in an autocrine or paracrine fashion. Taking these into consideration, a high level of serum HGF or IL-6 in patients with a small-sized prostate gland is considered to be evidence of the presence of cancer. Prostate cancer group: r =0.272, P =0.081
Benign group: r =0.201, P =0.0301
Prostate cancer group: r =0.489, P=0.001
Benign group: r =0.472, P< 0.0001 Figure 2 Correlations between HGF and IL-6 levels (a), and between HGFD and IL-6D levels (b) in patients with prostate cancer and benign groups, after adjustments for age. Significant positive correlations were observed between HGF and IL-6 (r ¼ 0.235, P ¼ 0.028), and between HGFD and IL-6D (r ¼ 0.521, Po0.0001) in all of the subjects.
Hepatocyte growth factor and interleukin-6 K Nishimura et al
In this study, median prostate volume was significantly higher in the benign groups than the prostate cancer group. Some investigators have reported that increased sampling errors account for the lower prostate cancer detection rate in prostate biopsy specimens from patients with a larger prostate volume. 19, 20 Recently reported data indicate that the current cancer detection rate ranges from 20 to 30% in patients with gray-zone PSA levels. 21 Emiliozzi et al. 22 reported that the cancer detection rates were 30 and 49% for 6-and 12-core transperineal biopsy, respectively, in patients with PSA levels between 4.1 and 10 ng ml
À1
. Thus, the cancer detection rate (35.3%) in the present study using a 10-core transperineal biopsy protocol was similar to previous reports. In addition, of the 117 cases with an initial negative biopsy in our study, 13 underwent a repeat biopsy, of whom three (23.1%) were diagnosed with prostate cancer (data not shown). The positive repeat biopsy rate in the benign group seems to be equal or lower than results reported previously, which ranges from 19 to 38.4%. 21 Therefore, our biopsy protocol is thought to have a lower sampling error rate, while the biopsy-proven benign population is considered reasonable for use as benign controls.
For early detection and screening for prostate cancer, useful tumor markers are required to reduce the number of unnecessary biopsies, while at the same time maintaining a high average cancer detection rate. In the present study, which utilized an HGFD cutoff value of 0.00541 ng ml À1 cm
À3
, after adjustments for age, 24.8% of the biopsies could have been avoided in the benign group, while still maintaining a high sensitivity of 95%. In addition, using a cutoff value of 0.00392 ng ml À1 cm À3 , 11.1% of the benign group could have avoided an unnecessary biopsy without missing prostate cancer. On the other hand, PSAD, IL-6 and IL-6D were significantly higher in the prostate cancer group as compared to the benign group, however, only 10.2, 4.3 and 10.2% of the biopsies could have been avoided in the benign group based on those respective values, while maintaining a high sensitivity of 95%. Therefore, PSAD, IL-6 and IL-6D values are considered important for cancer detection, while HGFD is useful for avoiding an unnecessary biopsy.
Although both HGF and IL-6 are recognized as pleiotropic growth factors involved in the progression of various types of cancer in an autocrine or paracrine manner, few studies have reported a relationship between them. Previously, it was demonstrated that administration of recombinant IL-6 induced increases in serum HGF levels in cancer patients. 23 Further, there were significant positive correlations between the levels of HGF and IL-6 in patients with breast cancer with liver metastasis. 24 In the present study, we found significant positive correlations between HGF and IL-6 and between HGFD and IL-6D in all patients, after adjustments for age, whereas no correlations of those factors were seen between the 2 groups (Figure 2 ). On the other hand, the levels of IL-6 in the prostate cancer group were significantly higher than in the benign group, whereas HGF levels were not different between the 2 groups. These findings suggest that IL-6 induces HGF production by prostate cells, whereas prostate cancer cells do not respond excessively, at least in patients with grayzone PSA levels.
In the present study, we used a PSA level of 2.7 ng ml À1 as the gray-zone cutoff, though the cutoff level generally accepted in western countries is 4.0 ng ml À1 . Our decision was based on the fact that the mean71.96 s.d. value of PSA in our PSA measuring kit (Lumipulse PSA-N) ranged from 0.27 to 2.7 ng ml
À1
, as well as a previous report that recommended 2.0 ng ml À1 as the cutoff value of serum PSA for a biopsy in Japanese men. 25 Among the 17 patients with serum PSA levels between 2.7 and 4.0 ng ml À1 in our study, prostate cancer was detected in two (11.8%) who would have been overlooked if 4.0 ng ml À1 had been used as the cutoff value. In addition, neither HGF nor IL-6 in combination with prostate volume was related to the risk of prostate cancer, after adjustments for age (data not shown). Therefore, it was considered that reliance on measurements of those growth factors might be disadvantageous for patients with serum PSA levels of o4.0 ng ml À1 .
Conclusion
We found that serum IL6, HGFD and IL-6D values were significantly higher in patients with prostate cancer than in benign controls with gray-zone PSA levels, after adjustments for age. In addition, those measurements were useful for the detection of prostate cancer and decreasing the number of unnecessary biopsies. This is the first known report of those growth factors in combination with prostate volume as useful parameters for prostate cancer screening in patients with gray-zone PSA levels. Therefore, with patients for whom PSA is considered to have a limited diagnostic potential, these new tumor markers may help to identify individuals with prostate cancer. However, additional investigations with larger numbers of subjects are needed to clarify their clinical value.
